Liposomal amphotericin B treatment of aspergillosis in a renal transplant patient

ABSTRACT

A renal transplant recipient developed intracranial aspergillosis, and whilst receiving conventional amphotericin B therapy [1 mg/kg daily] developed acute anuric renal failure necessitating discontinuation of therapy. He then received liposomal amphotericin B [Ambisome] at 2 mg/kg daily with no recurrence of renal toxicity. Liposomal amphotericin B appears to be safe in the management of severe fungal infections in renal transplant patients in whom preservation of renal function is crucial